Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I.
Serum PGI2 stabilizing factor (PSF) was purified from human serum to a single protein with a molecular weight of 28,000 D by SDS-PAGE. Analyses of NH2-terminal sequence (32 residues), COOH-terminal sequence (3 residues) and the composition of amino acids disclosed its homology with human apolipoprotein A-I (Apo A-I), a major apolipoprotein of HDL. Apolipoprotein A-II, C-I, C-II, C-III, D and E, as well as LDL, and VLDL did not possess this activity. The alpha-helix structure of Apo A-I is necessary for the binding of PGI2. HDL and nascent HDL reconstituted from Apo A-I and phospholipid significantly prolonged the half-life of PGI2. PGI2 stabilization by HDL and Apo A-I may be an important protective action against the accumulation of platelet thrombi at sites of vascular damage. The beneficial effect of HDL in the prevention of coronary artery disease may be partly due to this action.
D000595:Amino Acid Sequence; D001054:Apolipoproteins A / Q000097:blood* / Q000302:isolation & purification / Q000502:physiology; D004355:Drug Stability; D011464:Epoprostenol / Q000097:blood*; D006207:Half-Life; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood; D008297:Male; D008969:Molecular Sequence Data; D012709:Serum Albumin / Q000302:isolation & purification / Q000502:physiology
D001054:Apolipoproteins A; D008075:Lipoproteins, HDL; D012709:Serum Albumin; D011464:Epoprostenol